The Ins and Outs of Calcium in Heart Failure
Brian O'Rourke C ardiac excitation-contraction coupling is akin to a biophysical juggling act that involves fast and slow ion movements overlapping in time and space across several compartments. In response to sarcolemmal depolarization, Ca 2ϩ release from the large intracellular store in the sarcoplasmic reticulum (SR) is triggered by a rush of Ca 2ϩ from the extracellular space through L-type Ca 2ϩ channels into the very tiny junctional cleft (12 nm) to activate SR Ca 2ϩ release channels in a tightly controlled signal amplification step. Local inactivation of the L-type Ca 2ϩ channel mediated by the large junctional Ca 2ϩ spike (peaking at Ͼ50 mol/L) provides a mechanism of negative feedback on beat-to-beat Ca 2ϩ influx; thus, an abrupt change in the size of cytosolic Ca 2ϩ transient will impact the trigger for subsequent beats and reciprocally influence the SR Ca 2ϩ content in a process known as autoregulation. 1 Ca 2ϩ removal processes, although kinetically slower, also play a major role in shaping the Ca 2ϩ dynamics, and, ultimately, the contraction, of the myocyte. The 2 main pathways, Ca 2ϩ reuptake into the SR by the Ca 2ϩ ATPase (SERCA2A) and Ca 2ϩ efflux across the sarcolemma by the Na ϩ /Ca 2ϩ exchanger (NCX), compete for the job of removing Ca 2ϩ ions in a speciesdependent manner. In ventricular myocytes from rats and mice, Ϸ90% of the Ca 2ϩ decline during a transient is mediated by SERCA2A, whereas NCX contributes only Ϸ7% to Ca 2ϩ removal (the remainder is taken up by mitochondria or extruded from the cell by the sarcolemmal Ca 2ϩ ATPase). 2 In most large animals (eg, rabbits, dogs, cats, ferrets), some small animals (eg, guinea pigs and hamsters), and humans, 3 Ca 2ϩ removal by SERCA2A accounts for only 60% to 70% of the total, whereas NCX contributes 25% to 30%. 4 When the amplitude of the Ca 2ϩ transient reaches a steady state, Ca 2ϩ influx on each heartbeat must be matched by an equal amount of Ca 2ϩ efflux from the myocyte, or else intracellular Ca 2ϩ overload or depletion will occur. This is primarily accomplished by the so-called forward-mode action of NCX, a 3:1 exchange of extracellular Na ϩ for intracellular Ca 2ϩ . However, because the exchanger is electrogenic, and is also driven by the gradients of Na ϩ and Ca 2ϩ across the sarcolemma, the driving forces can switch to Ca 2ϩ entry and Na ϩ efflux (reverse-mode NCX) when the membrane potential is more positive than the NCX reversal potential, which can occur during the early repolarization phase 5 and the plateau of the cardiac action potential. 6 One of the more difficult challenges for cellular physiologists has been to determine the direction and magnitude of NCX current and Ca 2ϩ transport during excitation-contraction coupling, when the membrane potential, Na and Na ϩ channels and ii) permeability; the charged exchange inhibitor peptide (XIP), patterned after the autoinhibitory region of the cytoplasmic regulatory loop of the exchanger, is impermeable to membranes and so can only be applied acutely to excised membrane patches or slowly via a patchclamp pipette.
Pharmacological agents designed to inhibit NCX, such as KB-R7943, 7 also lack selectivity, inhibiting various ionic currents including I Na , I Ca,L , I K , I K1 , 8 as well as I TRPC , 9 with IC 50 values (Ͻ10 mol/L) close to that for NCX inhibition. Although it has been extensively used to investigate the role of NCX in ischemia/reperfusion injury, the lack of selectivity of KB-R7943 makes interpretation of the results quite difficult, because many of the alternate targets of the compound could theoretically contribute to the observed actions. The more recently developed SEA-0400 8 also inhibits I Ca with micromolar affinity 10 ; however, it is more potent than KB-R7943 against NCX (IC 50 Ϸ0.11 mol/L), 10 providing incentive to use it judiciously to readdress the central question about the role of NCX in excitation-contraction coupling in normal and diseased hearts.
An important application for NCX inhibitors is to ascertain the contribution of the exchanger to altered Ca 2ϩ handling in heart failure, 11 the subject of the report by Ozdemir et al 12 in this issue of Circulation Research. Numerous studies in human 3 and animal models 13, 14 of heart failure have reported that the relative contribution of SERCA2A decreases and that of NCX increases during Ca 2ϩ removal in myocytes isolated from failing hearts. For example, in the canine pacinginduced heart failure model that we have studied, there is a decrease in the SERCA2A activity and an increase in the NCX activity 15, 16 such that the normal 69:25% contributions of SERCA2A and NCX to total Ca 2ϩ removal change to 35:58%. Qualitatively similar remodeling takes place in many models of heart failure, but the extent of the decrease in SERCA2A and the increase in NCX varies among different animal models. This shift away from reloading the SR and toward Ca 2ϩ extrusion from the cell is thought to contribute to
The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.
From The Johns Hopkins University, School of Medicine, Division of Cardiology, Baltimore, Md.
diminished SR Ca 2ϩ content in heart failure. [13] [14] [15] On the other hand, there is evidence that the slightly longer action potentials and increased intracellular Na ϩ load of failing heart cells promotes more reverse-mode Ca 2ϩ entry during the action potential, which can contribute to contraction. 17 Therefore, it is of paramount importance to determine whether the inhibition of NCX increases or decreases SR Ca 2ϩ load in failing cardiomyocytes. Along these lines, we have previously investigated whether selective inhibition of NCX with XIP can improve the defects in SR Ca 2ϩ loading in a canine pacinginduced heart failure model. 18 We found that whereas partial inhibition of NCX (by Ϸ30%) had only modest effects on SR Ca 2ϩ load and the frequency dependence of the Ca 2ϩ transient in normal cells, the effect in failing cells was dramatic, with full restoration of the SR Ca 2ϩ content to normal levels and conversion of the flat frequency response of the Ca 2ϩ transient (characteristic of heart failure) to a positive staircase. Moreover, partial inhibition of NCX in the failing group also restored the amplitude and rate of rise of the transient to normal levels. Another interesting effect of XIP treatment in the canine model was that the rate of Ca 2ϩ removal via SERCA2A was enhanced on inhibition of NCX. This suggested that regulation of the pump by Ca 2ϩ may be a factor in the positive inotropic effect of XIP, but it remains to be determined whether similar effects are present in other models of heart failure.
The study by Ozdemir et al 12 addresses several key issues regarding the potential clinical utility of SEA-0400 as an inotropic agent in cardiac myocytes. First, it examines the selectivity, mode dependence, and efficacy of NCX inhibition, both with and without internal Ca 2ϩ buffering. Whereas previous studies have suggested that NCX inhibitor compounds were somewhat selective for the reverse-mode of NCX, the present study demonstrates that this depends on the particular experimental conditions used; with normal Na ϩ and Ca 2ϩ gradients and minimal intracellular buffering, SEA-0400 was about equally effective at blocking both modes of the exchanger at 0.3 or 1 mol/L concentrations. I Ca,L was partially inhibited, but the extent also depended on whether or not Ca 2ϩ was buffered. I Ca,L block was greater with less buffering, indicating that part of the Ca 2ϩ channel inhibition was indirectly related to the NCX-mediated changes in intracellular Ca 2ϩ . SEA-0400 significantly inhibited forwardmode NCX and increased SR Ca 2ϩ content and cell shortening in normal cardiomyocytes from both pigs and mice. In contrast, no positive inotropic effect was observed in a cardiomyopathic mouse knockout model of myosin LIM protein (MLP Ϫ/Ϫ ), a scaffold protein of the actin-based cytoskeleton, even though relaxation of the twitch was slowed. In contrast, SEA-0400 significantly improved contractility in a mouse model of heart failure induced by transverse aortic constriction.
An important conclusion from the study by Ozdemir et al 12 is that all models of heart failure are not equivalent, and a potential therapeutic strategy effective in one may not be useful in another. Thus, it behooves us to further examine the particular Ca 2ϩ handling alterations in each case and to examine the effects of NCX inhibition in both large and small animal models. The Ca 2ϩ handling properties of myocytes in the MLP Ϫ/Ϫ model have been investigated previously. Two groups 19, 20 reported a decrease in the amplitude of the Ca 2ϩ transient and cell shortening in myocytes from MLP Ϫ/Ϫ mice with no change in I Ca,L or Ca 2ϩ spark properties. In contrast, Su et al 21 found an increase in Ca 2ϩ transient amplitude (almost doubled) and SR Ca 2ϩ content (increased 21%), and a faster Ca 2ϩ decay rate in MLP Ϫ/Ϫ myocytes, but decreased fractional shortening, suggesting that defective Ca 2ϩ handling was not responsible for the depressed contractility in this model. Based on the latter findings, it is perhaps not surprising then that NCX inhibition did not mediate a positive inotropic effect in the MLP Ϫ/Ϫ model, because the primary defect may be myofilament disorganization. 21 In the transverse aortic constriction model, SEA-0400 was an effective positive inotropic agent, 12 consistent with reports that SERCA2A protein is decreased 22, 23 and NCX mRNA 24 is increased by modest amounts, although a detailed characterization of the rate constants for these processes in the transverse aortic constriction model has not been reported.
A skeptic could also question the relevance of using rat or mouse models to study the role of NCX in normal or pathophysiological conditions. As mentioned above, the contribution of NCX to total Ca 2ϩ removal in these species is roughly 4 times less than in larger mammals and humans; hence, the role of NCX has already been minimized by evolution. Of course, the overwhelming advantage of the mouse is the ability to manipulate its genome, yet transgenic knockout of NCX in this case has led to surprising results. Genetic ablation of NCX leads to embryonic lethality, 25 indicating that it plays an essential role in development, but conditional NCX knockout using a Cre/Lox expression system showed that only a modest global functional deficit was present under normal conditions 26 despite elimination of NCX1 in 80% to 90% of the myocytes (the Cre recombinase efficacy was not 100%). The explanation for why cardiac function is not severely compromised in NCX knockout mice is that marked remodeling of both the action potential and I Ca,L occur to substantially decrease the magnitude of Ca 2ϩ influx during each beat, without having a major effect on the ability to trigger Ca 2ϩ release. 26 Apparently, in adult myocytes, the smaller net uptake of Ca 2ϩ over many beats is adequately extruded by the sarcolemmal Ca 2ϩ pump, although in embryonic myotubes from NCX knockout mice, this capacity may be exceeded when Ca 2ϩ influx is enhanced. 27 Although this makes it difficult to use the knockout to define the role of NCX in normal myocytes, it speaks to the critical requirement for balancing Ca 2ϩ influx and efflux, accomplished by a remarkably plasticity extending beyond acute autoregulation of Ca 2ϩ fluxes. This is underscored by opposite adaptations leading to increased Ca 2ϩ influx in NCX-overexpressing transgenic mice. 28 In summary, the study by Ozdemir et al 12 provides valuable insight into the potential for NCX inhibitors as inotropic agents in heart failure and confirms that SEA-0400 is approximately equipotent at blocking both the forward and reverse modes of NCX when intracellular Ca 2ϩ is minimally buffered, with the net effect being to increase SR Ca 2ϩ content in pig and mouse myocytes. However, the efficacy of agents like SEA-0400 in heart failure may be completely dependent on the specific alterations in Ca 2ϩ handling present in the model. Moreover, the possible benefits must be carefully assessed in light of the importance of NCX in the beat-to-beat removal of Ca 2ϩ from the myocyte, which can only be determined by further studies in large animals.
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